ES2095938T3 - Procedimiento y composiciones para el tratamiento de lesiones. - Google Patents
Procedimiento y composiciones para el tratamiento de lesiones.Info
- Publication number
- ES2095938T3 ES2095938T3 ES91909076T ES91909076T ES2095938T3 ES 2095938 T3 ES2095938 T3 ES 2095938T3 ES 91909076 T ES91909076 T ES 91909076T ES 91909076 T ES91909076 T ES 91909076T ES 2095938 T3 ES2095938 T3 ES 2095938T3
- Authority
- ES
- Spain
- Prior art keywords
- injuries
- compositions
- procedure
- treatment
- chemotherapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000006378 damage Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 102100032352 Leukemia inhibitory factor Human genes 0.000 abstract 1
- 108090000581 Leukemia inhibitory factor Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 239000000356 contaminant Substances 0.000 abstract 1
- 230000001120 cytoprotective effect Effects 0.000 abstract 1
- 230000005865 ionizing radiation Effects 0.000 abstract 1
- 238000001556 precipitation Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 231100000816 toxic dose Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5415—Leukaemia inhibitory factor [LIF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
SE UTILIZAN EL FACTOR D, LA HORMONA DEL CRECIMIENTO, EL IL-1 Y LOS FACTORES DE NECROSIS TUMORALES, SOLOS O EN COMBINACION, COMO AGENTES CITOPROTECTORES SINERGISTICOS PARA PACIENTES EXPUESTOS A DOSIS TOXICAS DE RADIACION IONIZANTE Y/O QUIMIOTERAPIA. SE SUMINISTRAN REGIMENES CITOPROTECTORES SINERGISTICOS QUE SON PARTICULARMENTE UTILES EN LA REDUCCION DE LA MORBIDIDAD Y DE LA MORTALIDAD EN TERAPIAS CONTRA EL CANCER. SE DESCRIBE EL USO DEL FACTOR D, DE LA HORMONA DEL CRECIMIENTO, DEL IL-1 Y DE LOS FACTORES DE NECROSIS TUMORALES, SOLOS O EN COMBINACION, PARA LA PREVENCION Y EL TRATAMIENTO DE LA ALOPECIA. SE PURIFICA EL FACTOR D MEDIANTE LA PRECIPITACION DE PROTEINAS CONTAMINANTES A UN PH MUY ACIDO Y SE ALMACENA DE FORMA ESTABLE A DICHO PH.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50734190A | 1990-04-10 | 1990-04-10 | |
US60284990A | 1990-10-26 | 1990-10-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2095938T3 true ES2095938T3 (es) | 1997-03-01 |
Family
ID=27055814
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES91909076T Expired - Lifetime ES2095938T3 (es) | 1990-04-10 | 1991-04-09 | Procedimiento y composiciones para el tratamiento de lesiones. |
Country Status (11)
Country | Link |
---|---|
US (2) | US5843422A (es) |
EP (2) | EP0527852B2 (es) |
JP (1) | JP3266248B2 (es) |
AT (1) | ATE144711T1 (es) |
CA (1) | CA2078544C (es) |
DE (1) | DE69122960T3 (es) |
DK (1) | DK0527852T3 (es) |
ES (1) | ES2095938T3 (es) |
GR (1) | GR3022097T3 (es) |
IL (1) | IL97779A (es) |
WO (1) | WO1991015227A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5370870A (en) * | 1989-10-06 | 1994-12-06 | Genentech, Inc. | Method for protection against reactive oxygen species |
US5200176A (en) * | 1989-10-06 | 1993-04-06 | Genentech, Inc. | Method for protection of ischemic tissues using tumor nerosis factor |
IL97779A (en) * | 1990-04-10 | 2000-01-31 | Genentech Inc | Compositions for cytoprotection against radiation and chemotherapy injury or risk thereof |
ES2084190T3 (es) * | 1990-10-25 | 1996-05-01 | Genentech Inc | Utilizacion de agentes protectores contra especies de oxigeno reactivas. |
US5460810A (en) * | 1992-09-02 | 1995-10-24 | Genetics Institute, Inc. | Method for maintaining gut epithelial cells by treatment with a cytokine such as interleukin 11 |
US7602940B2 (en) | 1998-04-16 | 2009-10-13 | Digimarc Corporation | Steganographic data hiding using a device clock |
FR2786104B1 (fr) * | 1998-11-25 | 2002-12-27 | Centre Nat Rech Scient | Inhibiteurs de l'activation de nf-kb, et leurs utilisations pharmaceutiques |
US8288366B2 (en) | 2006-06-20 | 2012-10-16 | Chochinov Ronald H | Formulation for hair growth |
WO2011042056A1 (en) * | 2009-10-08 | 2011-04-14 | United Technologies Ut Ag | Cosmetic method for treatment of skin and hair with cosmetic compositions containing interleukin-1 |
JP5913479B2 (ja) * | 2014-08-11 | 2016-04-27 | リゼロン、インク. | ヒト成長ホルモンを有効成分として含む発毛の促進用の組成物 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4321832A (en) * | 1980-03-07 | 1982-03-30 | Rockwell International Corporation | High accuracy measuring apparatus |
IL75318A (en) * | 1984-05-31 | 1994-08-26 | Genentech Inc | Recombinant human memotoxin and methods for its recombinant production |
GR851626B (es) * | 1984-07-05 | 1985-11-26 | Genentech Inc | |
WO1987005519A1 (en) * | 1986-03-14 | 1987-09-24 | Schering Corporation | Treatment of cancer with interferon and radiotherapy |
DE3613167A1 (de) † | 1986-04-18 | 1987-10-29 | Basf Ag | Verwendung von tnf zur herstellung von arzneimitteln |
IL80005A (en) * | 1986-09-10 | 1992-11-15 | Yeda Res & Dev | Compositions for modulating the effect of tnf and il-1 |
US4985241A (en) * | 1986-11-21 | 1991-01-15 | Cetus Corporation | Therapeutic combination of free-radical scavenger and tumor necrosis factor |
PT87133B (pt) * | 1987-04-02 | 1992-07-31 | Amrad Corp Ltd | Metodo de purificacao do factor inibidor da leucemia (lif) e de composicoes farmaceuticas contendo polipeptidos com actividade do lif |
ZA893063B (en) * | 1988-04-27 | 1990-01-31 | Immunomedics Inc | Improved radiotherapy |
WO1990002183A1 (en) * | 1988-08-18 | 1990-03-08 | Genetics Institute, Inc. | Production of a novel lymphokine exhibiting differentiation inhibitory activity |
EP0463004A4 (en) * | 1989-03-07 | 1992-04-01 | Amrad Corporation Limited | Metabolic effects of leukaemia inhibitory factor on bone |
US5370870A (en) * | 1989-10-06 | 1994-12-06 | Genentech, Inc. | Method for protection against reactive oxygen species |
IL97779A (en) * | 1990-04-10 | 2000-01-31 | Genentech Inc | Compositions for cytoprotection against radiation and chemotherapy injury or risk thereof |
US5202119A (en) * | 1991-06-28 | 1993-04-13 | Genentech, Inc. | Method of stimulating immune response |
-
1991
- 1991-04-04 IL IL9777991A patent/IL97779A/xx not_active IP Right Cessation
- 1991-04-09 EP EP91909076A patent/EP0527852B2/en not_active Expired - Lifetime
- 1991-04-09 DK DK91909076.1T patent/DK0527852T3/da active
- 1991-04-09 AT AT91909076T patent/ATE144711T1/de not_active IP Right Cessation
- 1991-04-09 CA CA002078544A patent/CA2078544C/en not_active Expired - Lifetime
- 1991-04-09 ES ES91909076T patent/ES2095938T3/es not_active Expired - Lifetime
- 1991-04-09 JP JP50880491A patent/JP3266248B2/ja not_active Expired - Fee Related
- 1991-04-09 WO PCT/US1991/002446 patent/WO1991015227A1/en active IP Right Grant
- 1991-04-09 EP EP96101245A patent/EP0731109A1/en not_active Withdrawn
- 1991-04-09 DE DE69122960T patent/DE69122960T3/de not_active Expired - Lifetime
-
1993
- 1993-06-10 US US08/076,086 patent/US5843422A/en not_active Expired - Lifetime
-
1995
- 1995-03-28 US US08/411,224 patent/US5725851A/en not_active Expired - Lifetime
-
1996
- 1996-12-18 GR GR960403545T patent/GR3022097T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP0731109A1 (en) | 1996-09-11 |
EP0527852A1 (en) | 1993-02-24 |
JPH05506663A (ja) | 1993-09-30 |
DE69122960T2 (de) | 1997-04-03 |
EP0527852B2 (en) | 2001-02-21 |
DE69122960D1 (de) | 1996-12-05 |
AU7856591A (en) | 1991-10-30 |
WO1991015227A1 (en) | 1991-10-17 |
IL97779A (en) | 2000-01-31 |
IL97779A0 (en) | 1992-06-21 |
AU638839B2 (en) | 1993-07-08 |
US5725851A (en) | 1998-03-10 |
CA2078544C (en) | 2008-02-26 |
US5843422A (en) | 1998-12-01 |
DE69122960T3 (de) | 2002-05-29 |
EP0527852B1 (en) | 1996-10-30 |
GR3022097T3 (en) | 1997-03-31 |
ATE144711T1 (de) | 1996-11-15 |
DK0527852T3 (es) | 1997-02-17 |
CA2078544A1 (en) | 1991-10-11 |
JP3266248B2 (ja) | 2002-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK358384D0 (da) | Farmaceutiske midler til bekaempelse af diabetes mellitus | |
DK387889A (da) | Makrolider, og farmaceutiske praeparater med indhold af saadanne forbindelser | |
DK108491D0 (da) | Nucleosider og nucleosidanaloge samt farmaceutiske praeparater indeholdende disse forbindelser | |
TW229156B (es) | ||
DK0582318T3 (da) | Udnyttelse af de anticarcinogene og antivirale egenskaber hos carnosinsyre | |
KR0141913B1 (en) | Anti-virus agents | |
ATE181329T1 (de) | Substituierte dibenzooxazepin-verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung | |
ES2095938T3 (es) | Procedimiento y composiciones para el tratamiento de lesiones. | |
NZ212768A (en) | 2-substituted-1,3-propylidene diphosphonate derivatives and pharmaceutical compositions | |
AU5670690A (en) | Lysolecithin derivatives for treating autoimmune diseases | |
NO923199D0 (no) | Terapeutiske forbindelser | |
FI945975A0 (fi) | Haarautuneella aminoryhmällä substituoituja tiatsoleja, menetelmiä niiden valmistamiseksi ja niitä sisältäviä farmaseuttisia koostumuksia | |
BR9302197A (pt) | Compostos fenilbenzamidas fungicidas,processo para suas preparacoes,composicao fungicida e processo para a protecao de plantas contra doencas fungicas | |
FI923664A0 (fi) | Piperidinderivat. | |
ZA886097B (en) | Pharmaceutical composition for the treatment of psoriasis | |
ES2102772T3 (es) | Compuesto citotoxico y antiviral. | |
ATE69238T1 (de) | Monoalkylester-sulfate von glutathion und verfahren zu deren herstellung. | |
ATE113477T1 (de) | Therapeutisch wirksames stoffgemisch aus glutathion- und anthocyan-verbindungen. | |
PT91153A (pt) | Processo para a preparacao de um ester de 9-(2-hidroxi-etoxi-metil)guanina e de composicoes que contem | |
FI923662A0 (fi) | Terapeutiska medel. | |
DK656889A (da) | Azabicykliske derivater | |
SE9101586L (sv) | Modifierat tioredoxin och dess anvaendning | |
ATE155470T1 (de) | Cephem verbindungen mit antimicrobizide eigenschaften |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 527852 Country of ref document: ES |